vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $50.4M, roughly 1.5× Armour Residential REIT, Inc.). On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 27.7%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 31.3%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
ARR vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $75.5M |
| Net Profit | $211.7M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 420.2% | — |
| Revenue YoY | 297.9% | 27.7% |
| Net Profit YoY | 555.9% | — |
| EPS (diluted) | $2.43 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $75.5M | ||
| Q3 25 | $38.5M | $54.5M | ||
| Q2 25 | $33.1M | $52.4M | ||
| Q1 25 | $36.3M | $46.0M | ||
| Q4 24 | $12.7M | $59.1M | ||
| Q3 24 | — | $80.5M | ||
| Q2 24 | $7.0M | $47.1M | ||
| Q1 24 | — | $43.8M |
| Q4 25 | $211.7M | — | ||
| Q3 25 | $159.3M | $8.8M | ||
| Q2 25 | $-75.6M | $5.9M | ||
| Q1 25 | $27.3M | $3.0M | ||
| Q4 24 | $-46.4M | — | ||
| Q3 24 | — | $20.3M | ||
| Q2 24 | $-48.4M | $-4.5M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | — | -5.3% |
| Q4 25 | 420.2% | — | ||
| Q3 25 | 413.5% | 16.2% | ||
| Q2 25 | -228.4% | 11.2% | ||
| Q1 25 | 75.2% | 6.5% | ||
| Q4 24 | -366.8% | — | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | -693.8% | -9.6% | ||
| Q1 24 | — | -11.0% |
| Q4 25 | $2.43 | $0.26 | ||
| Q3 25 | $1.49 | $0.17 | ||
| Q2 25 | $-0.94 | $0.12 | ||
| Q1 25 | $0.32 | $0.06 | ||
| Q4 24 | $-0.91 | $0.40 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | $-1.05 | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $2.3B | $130.3M |
| Total Assets | $21.0B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $97.5M | ||
| Q3 25 | $44.2M | $94.4M | ||
| Q2 25 | $141.2M | $96.0M | ||
| Q1 25 | $49.1M | $93.2M | ||
| Q4 24 | $68.0M | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | $126.6M | $96.8M | ||
| Q1 24 | — | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $2.3B | $130.3M | ||
| Q3 25 | $2.1B | $115.3M | ||
| Q2 25 | $1.7B | $104.7M | ||
| Q1 25 | $1.7B | $97.1M | ||
| Q4 24 | $1.4B | $92.1M | ||
| Q3 24 | — | $71.1M | ||
| Q2 24 | $1.2B | $48.5M | ||
| Q1 24 | — | $51.0M |
| Q4 25 | $21.0B | $216.3M | ||
| Q3 25 | $19.4B | $202.9M | ||
| Q2 25 | $16.2B | $194.9M | ||
| Q1 25 | $15.5B | $196.2M | ||
| Q4 24 | $13.5B | $213.3M | ||
| Q3 24 | — | $220.7M | ||
| Q2 24 | $10.1B | $205.0M | ||
| Q1 24 | — | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $14.4M | ||
| Q3 25 | $-37.8M | $9.7M | ||
| Q2 25 | $25.0M | $14.1M | ||
| Q1 25 | $101.5M | $3.6M | ||
| Q4 24 | $261.5M | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | $27.1M | $1.0M | ||
| Q1 24 | — | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 3.71× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
